ARTICLE | Clinical News

Idenix reports data for IDX21437

April 8, 2014 1:26 AM UTC

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) gained $0.64 (12%) to $5.81 on Monday after reporting that once-daily 300 mg IDX21437 for seven days led to a mean maximum reduction in viral load of 4.2-4.3 log10 IU/mL in 18 evaluable treatment-naïve patients in a Phase I/II trial to treat HCV genotypes 1, 2 or 3 infection. The trial enrolled 44 patients to receive placebo or once-daily 50, 150 or 300 mg IDX21437.

Mid-year, Idenix plans to start a Phase II trial to evaluate the once-daily 300 mg dose of IDX21437 in combination with the company's samatasvir ( IDX719) to treat HCV genotypes 1, 2 and 3 infection. Samatasvir is an HCV NS5A protein inhibitor in Phase II testing for HCV infection. IDX21437 is a uridine nucleotide analog HCV NS5B polymerase inhibitor. ...